Serum Soluble Interleukin-2 Receptor Levels are Associated with Clinical Disease Status and Histopathological Grade in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

References

• Rubin L., Kurman C., Fritz M., Biddison W., Boutin B., Yarchoan R., Nelson D. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. Journal of Immunology 1985; 135: 3172–3177
   PubMed Web of Science ®Google Scholar
• Hancock W., Muller W., Cotran R. Interleukin 2 receptors are expressed by alveolar macrophages during pulmonary sarcoidosis and are inducible by lymphokine treatment of normal human lung macrophages, blood monocytes, and monocyte cell lines. Journal of Immunology 1987; 138: 1885–191
   Google Scholar
• Durn A. G., Ho D. D., Schooley R. T., Hirsch M. S., Mackeen L., Ip S. H. Serum interleukin-2 receptor (IL-2R)levels in human immunodeficiency virus (HIV) infection. Blood 1986; 68(Suppl. 1)124a
   Google Scholar
• Medina-Ibbarrondo C., Lahuerta-Palacios J. J., Lahuerta-Palacios M. Soluble interleukin-2 receptors in B-cell leukemia and the acquired immunodeficiency syndrome. Annals of Internal Medicine 1987; 106: 774
   PubMed Web of Science ®Google Scholar
• Greene W. C., Leonard W. J., Depper J. M., Nelson D. L., Waldmann T. A. The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T-lymphotropic retroviruses. Annals of Internal Medicine 1986; 105: 560–572
   PubMed Web of Science ®Google Scholar
• Pizzolo R., Chilosi H., Josimovic-Alasevic O., Vinante F., Zanotti R., Chilosi M., Keller A. C., Diamanstein D. Increased serum levels of soluble IL-2 receptor, CD30, and CD8 molecules and gamma interferon in angioimmunoblastic lymphadenopathy. Possible pathogenetic role of immunoacti-vation mechanisms. British Journal of Hematology 1990; 75: 484–488
   Google Scholar
• Delforge A., Bernier M., Bosmans E., Massy M., et al. Measurement of soluble Interleukin 2 receptor in sera of adult patients with haematological or solid malignancies. Leukemia and Lymphoma 1991; 3: 385–394
   PubMed Web of Science ®Google Scholar
• Pui C., Ip S., Kung P., Dodge R., Berard C., Crist W., Murphy S. High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. Blood 1987; 70: 624–628
   PubMed Web of Science ®Google Scholar
• Wagner D., Kiwanuka J., Edwards B., Rubin L., Nelson D., Magrath I. Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: Correlation with survival. Journal of Clinical Oncology 1987; 5: 1262–1270
   PubMed Web of Science ®Google Scholar
• Marcon L., Rubin L., Kurman C., Fritz M., Longo D., Uchiyama T., Edwards B., Nelson D. Elevated serum levels of soluble Tac peptide in adult T-cell leukemia: Correlation with clinical status during chemotherapy. Annals of Internal Medicine 1988; 109: 274–279
   PubMed Web of Science ®Google Scholar
• Kay N., Burton J., Wagner D., Nelson D. The malignant B cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukin-2 receptors. Blood 1988; 72: 447–450
   PubMed Web of Science ®Google Scholar
• Semenzato G., Foa R., Agostini C., Zambellow R., Trentin L., Vinante F., Benedettik R., Chilosi M., Pizzolo G. High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. Blood 1987; 70: 396–400
   PubMed Web of Science ®Google Scholar
• Chilosi M., Pizzolo G., Semenzato G., Cetto G. L. Detection of a soluble form of the receptor for interleukin-2 in the serum of patients with hairy cell leukaemia. International Journal of Biological Markers 1986; 1: 101–104
   PubMedGoogle Scholar
• Ho A., Haas R., Wulf G., Knauf W., Ehrhardt R., Heilig B., Korbling M., Schulz G., Hunstein W. Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma. Blood 1990; 745: 203–212
   Google Scholar
• Lauria F., Rondelli D., Raspadori D., et al. Serum soluble Interleukin 2 receptor levels in Hairy Cell Leukemia: Correlation with clinical and hematological parameters and with alpha-Interferon treatment. Leukemia and Lymphoma 1992; 6, in press
   Google Scholar
• Pizzolo G., Chilosi M., Semanzato G. The soluble interleukin-2 receptor in haematological disorders. British Journal of Haematology 1987; 67: 377–380
   PubMed Web of Science ®Google Scholar
• Yasuda N., Lai P. K., Ip S. H., Kung P. C., Matsuoka M., Hattori T., Takatsuki K., Purtilo D. T. Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 1988; 71: 1021–1026
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Chilosi M., Vinante F., Dazzi R., Lestani M., Perona G., Perini A., Benedetti F., Todeschini G., Vincenzi C., Trentin L., Semenzato G. Soluble Interleukin-2 receptors in the serum of patients with Hodgkin's disease. British Journal of Cancer 1987a; 55: 427–428
   PubMed Web of Science ®Google Scholar
• Steis R. G., Marcon L., Clark J., Urba W., Longo D. L., Nelson D. L., Maluish A. E. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 1988; 71: 1304–1309
   PubMed Web of Science ®Google Scholar
• Ambrosetti A., Semenzato G., Prior M., Chilosi M., Vinante F., Vincenzi C., Zanotti R., Trentin L., Portuese A., Menestrina F., Perona G., Agostini C., Pizzolo G. Serum levels of soluble interleukin-2 receptor in hairy cell leukemia; a reliable marker of neoplastic bulk. British Journal of Hematology 1989; 773: 191–186
   Google Scholar
• Richards J. M., Mick R., Latta J. M., Daly K., Ratain M. J., Vardiman J. W., Golomb H. M. Serum soluble interleukin-2 receptor is associated with clinical and pathological disease status in hairy cell leukemia. Blood 1990; 76: 1941–1945
   PubMed Web of Science ®Google Scholar
• Chilosi M., Semenzato G., Cetto G., Ambrosetti A., Fiore-Donati L., Perona G., Berton G., Lestani M., Scarpa A., Agostini C., Trentin L., Zambello R., Masciarelli M., Dazzi F., Vinante F., Caligaris-Cappio F., Pizzolo G. Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-Interferon therapy on clinical parameters and natural killer in vitro activity. Blood 1987; 70: 1530–1535
   PubMed Web of Science ®Google Scholar
• Pizzolo G., Dallenbach F., Vinante F., et al. High serum levels of soluble Interleukin-2 receptor and absence of detectable levels of soluble CD30 molecule: A specific diagnostic combination for Hairy Cell Leukemia. Leukemia and Lymphoma 1992; 5, in press.
   Google Scholar
• Chilosi M., Semenzato G., Vinante F., Menestrina F., Piazzola E., Focchiatti V., Sabbioni R., Zanotti R., Pizzolo G. Increased levels of soluble interleukin 2 receptor in non-Hodgkin's lymphomas. American Journal of Clinical Pathology 1989; 92: 186–191
   PubMed Web of Science ®Google Scholar
• Gause A., Roschansky V., Tschiersch A., Smith K., Hasenclever D., Schmits R., Diehl V., Pfreundschuh M. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma. Annals of Oncology 1991; 2(S2)43–47
   PubMedGoogle Scholar
• Pui C. H. Serum interleukin-2 receptor: clinical and biological implications. Leukemia 1989; 3: 323–333
   PubMed Web of Science ®Google Scholar
• Semenzato G., Trentin L., Zambello R., Agostini C., Bulian P., Siviero F., Ambroseetti A., Vinante F., Prior M., Chilosi M. Origin of the soluble interleukin-2 receptor in the serum of patients with hairy cell leukemia. Leukemia 1988; 2: 788
   PubMed Web of Science ®Google Scholar
• Motoi T., Uchiyama T., Hori T., Itoh K., Ulchino H., Ueda R. Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blast crisis. Blood 1989; 74: 1052
   PubMed Web of Science ®Google Scholar
• Ayanlar-Batuman O., Shevitz J., Traub U., Murphy S., Sajewski D. Lymphocyte interleukin 2 production and responsiveness are altered in patients with primary myelodys-plastic syndromes. Blood 1987; 70: 494–500
   PubMed Web of Science ®Google Scholar
• Jung L., Hara T., Man Fu S. Detection and functional studies of p60–65 (Tac antigen) on activated human B cells. Journal of Experimental Medicine 1984; 160: 1597–1602
   PubMed Web of Science ®Google Scholar
• Walkmann T., Goldman C., Robb R., Depper J., Leonard W., Sharrow S., Bongiovann K., Korsmeyer S., Greene W. Expression of interleukin 2 receptors on activated human B cells. Journal of Experimental Medicine 1984; 160: 1450–1456
   PubMed Web of Science ®Google Scholar
• Trinchieri G., Matsumoto-Kobayashi M., Clark S., Seehar J., London L., Perussia B. Response of resting human peripheral blood natural killer cells to interleukin-2. Journal of Experimental Medicine 1984; 160: 1147–1152
   PubMed Web of Science ®Google Scholar
• Pui C. H., Ip S., Iflah S., et al. Serum interleukin-2 receptor levels in childhood acute lymphoblastic leukemia. Blood 1988; 71: 1135–1137
   PubMed Web of Science ®Google Scholar
• National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical usage. The non-Hodgkin's lymphoma pathologic classification project. Cancer 1982; 49: 2112–2115
   PubMed Web of Science ®Google Scholar
• Rai K. R., Sawitsky A., Cronkite E. P., et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219–234
   PubMed Web of Science ®Google Scholar
• Binet J., Auquier A., Dighiero G., Chastang C., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198
   PubMed Web of Science ®Google Scholar